Metformin Hydrochloride; Sitagliptin Phosphate is used for managing type 2 diabetes mellitus with the combination of sitagliptin and metformin HCl extended release, either alone or with insulin. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc in its drug Janumet on Mar 30, 2007. Another drug containing Metformin Hydrochloride; Sitagliptin Phosphate is Janumet Xr.

Metformin Hydrochloride; Sitagliptin Phosphate Patents

Given below is the list of patents protecting Metformin Hydrochloride; Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Janumet	US8414921 (Pediatric)	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jan 21, 2029	Msd Sub Merck
Janumet	US8414921	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jul 21, 2028	Msd Sub Merck
Janumet	US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May 24, 2027	Msd Sub Merck
Janumet Xr	US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May 24, 2027	Msd Sub Merck
Janumet	US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	Nov 24, 2026	Msd Sub Merck
Janumet Xr	US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	Nov 24, 2026	Msd Sub Merck
Janumet	US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan 26, 2023 (Expired)	Msd Sub Merck
Janumet	US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan 26, 2023 (Expired)	Msd Sub Merck
Janumet Xr	US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan 26, 2023 (Expired)	Msd Sub Merck
Janumet Xr	US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan 26, 2023 (Expired)	Msd Sub Merck
Janumet	US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul 26, 2022 (Expired)	Msd Sub Merck
Janumet	US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul 26, 2022 (Expired)	Msd Sub Merck
Janumet Xr	US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul 26, 2022 (Expired)	Msd Sub Merck
Janumet Xr	US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul 26, 2022 (Expired)	Msd Sub Merck
Janumet	US6890898	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet	US7078381	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet	US7459428	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet Xr	US6890898	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet Xr	US7078381	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet Xr	US7459428	Method of regulating glucose metabolism, and reagents related thereto	Feb 02, 2019 (Expired)	Msd Sub Merck
Janumet	US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	Apr 24, 2017 (Expired)	Msd Sub Merck
Janumet Xr	US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	Apr 24, 2017 (Expired)	Msd Sub Merck
Janumet Xr	US6340475	Extending the duration of drug release within the stomach during the fed mode	Sep 19, 2016 (Expired)	Msd Sub Merck
Janumet Xr	US6635280	Extending the duration of drug release within the stomach during the fed mode	Sep 19, 2016 (Expired)	Msd Sub Merck

Add above patents to watchlist

Metformin Hydrochloride; Sitagliptin Phosphate's Family Patents

Full family tree